Pre-made Vofatamab benchmark antibody ( Whole mAb, anti-FGFR3 therapeutic antibody, Anti-ACH/CEK2/JTK4/CD333/HSFGFR3EX Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Vofatamab biosimilar, Whole mAb, Anti-FGFR3 Antibody: Anti-ACH/CEK2/JTK4/CD333/HSFGFR3EX therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vofatamab (B-701, Rainier Therapeutics) is an antibody that targets fibroblast growth factor receptor 3 (FGFR3), an established driver of bladder cancer and other malignancies.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-626-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Vofatamab biosimilar, Whole mAb, Anti-FGFR3 Antibody: Anti-ACH/CEK2/JTK4/CD333/HSFGFR3EX therapeutic antibody
INN Name	Vofatamab
Target	FGFR3
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	4wv1:BA:ED/3grw:HL
Year Proposed	2018
Year Recommended	2019
Companies	BioClin Therapeutics;Rainier Therapeutics
Conditions Approved	na
Conditions Active	Urogenital cancer
Conditions Discontinued	Multiple myeloma;Solid tumours;Achondroplasia
Development Tech	na